(170 days)
Not Found
No
The description details a standard real-time PCR assay with automated processing and signal interpretation based on predefined thresholds, not AI/ML algorithms.
No
The device is an in vitro diagnostic test intended to aid in the prevention and control of MRSA infections by detecting MRSA DNA. It is specifically stated that "It is not intended to diagnose, guide or monitor MRSA infections." This indicates it's for diagnostic purposes, not therapeutic intervention or treatment.
Yes
The device is described as an "automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs," which clearly indicates its purpose is diagnostic, even if it's "not intended to diagnose, guide or monitor MRSA infections." It aids in the prevention and control of MRSA infections by detecting colonization.
No
The device description clearly outlines a system that includes hardware components for sample processing, DNA extraction, amplification, and detection using real-time PCR and optical channels. While software is involved in data interpretation, it is integral to a larger hardware system.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "The BD MAX™ MRSA Assay performed on the BD MAX™ System is an automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization."
This statement directly identifies the device as an in vitro diagnostic test.
N/A
Intended Use / Indications for Use
The BD MAX™ MRSA Assay performed on the BD MAX™ System is an automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX™ MRSA Assay is intended to aid in the prevention and control of MRSA infections in healthcare settings. It is not intended to diagnose, guide or monitor MRSA infections. A negative result does not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.
Product codes (comma separated list FDA assigned to the subject device)
NQX, OOI
Device Description
A nasal specimen is collected and transported to the laboratory using the recommended swab. The swab is placed in a BD MAX™ MRSA Sample Buffer Tube. The Sample Buffer Tube is vortexed to release cells from the swab into the buffer. The Sample Buffer Tube is placed onto the BD MAX™ System and the following automated procedures occur: the bacterial cells are lysed, DNA is extracted on magnetic beads and concentrated, then an aliquot of the eluted DNA is added to PCR reagents which contain the MRSA-specific primers used to amplify the genetic target, if present. The assay also includes a Sample Processing Control (SPC). The Sample Processing Control is present in the Extraction Tube and undergoes the extraction and amplification steps to monitor for inhibitory substances as well as process inefficiency due to instrument or reagent failure. No operator intervention is necessary once the clinical sample and reagent strip are loaded into the BD MAX™ System. The BD MAX™ System automates sample lysis, DNA extraction and concentration, reagent rehydration, nucleic acid amplification and detection of the target nucleic acid sequence using real-time polymerase chain reaction (PCR). Amplified targets are detected with hydrolysis probes labeled with quenched fluorophores. The amplification, detection and interpretation of the signals are done automatically by the BD MAX™ System.
The BD MAX™ System uses a combination of lytic and extraction reagents to perform cell lysis and DNA extraction. Following enzymatic cell lysis at elevated temperature, the released nucleic acids are captured by magnetic affinity beads. The beads with the bound nucleic acids are washed and the nucleic acids are eluted by heat in Elution Buffer. Eluted DNA is neutralized with Neutralization Buffer and transferred to the Master Mix Tube to rehydrate PCR reagents. The reconstituted amplification reagent is dispensed into the BD MAX™ PCR Cartridge. Microvalves in the BD MAX™ PCR Cartridge are sealed by the system prior to initiating PCR to prevent evaporation and amplicon contamination.
The amplified DNA targets are detected using hydrolysis (TagMan®) probes labeled at one end with a fluorescent reporter dye (fluorophore) and at the other end with a quencher moiety. Probes labeled with different fluorophores are used to detect MRSA and SPC amplicons in two different optical channels of the BD MAX™ System: MRSA amplicons are detected in the FAM channel and SPC amplicons are detected in the ROX channel. When the probes are in their native state, the fluorescence of the fluorophore is quenched due to its proximity to the quencher. However, in the presence of target DNA, the probes hybridize to their complementary sequences and are hydrolyzed by the 5'-3' exonuclease activity of the DNA polymerase as it synthesizes the nascent strand along the DNA template. As a result, the fluorophores are separated from the quencher molecules and fluorescence is emitted. The amount of fluorescence detected in the two optical channels used for the BD MAX™ MRSA Assay is directly proportional to the quantity of the corresponding probe that is hydrolyzed. The BD MAX™ System measures these signals at the end of each amplification cycle, and interprets the data to provide a result.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Nasal swabs
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Healthcare settings
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Four (4) investigational centers participated in a multi-site prospective investigational study.
The Comparative Reference Method consisted of direct culture complemented by enriched culture. Enriched culture analysis was completed for all specimens that were negative for MRSA by direct culture. Presumptive S. aureus colonies observed on selective (S. aureus) chromogenic media were subcultured onto Blood Agar (BA). Identification was confirmed with an agglutination test, while Methicillin-resistance was confirmed by Cefoxitin disk (30μg) diffusion susceptibility testing. Enrichment in Trypticase Soy Broth with 6.5% NaCl (TSB 6.5% NaCl) was completed in the event that Methicillin-resistant S. aureus was not confirmed by the initial direct culture method. Turbid TSB 6.5% NaCl broth was used to inoculate additional chromogenic media and BA plates; MRSA confirmation was performed as described above.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical performance characteristics were determined in a multi-site prospective investigational study.
Overall sample size: 1903 reference method compliant specimens.
Sensitivity: 93.0% (146/157) with 95% CI (87.9%, 96.0%)
Specificity: 95.9% (1653/1724) with 95% CI (94.8%, 96.7%)
Positive Agreement (compared to Direct Culture): 95.0% (133/140) with 95% CI (90.0%, 97.6%)
Negative Agreement (compared to Direct Culture): 95.2% (1657/1741) with 95% CI (94.1%, 96.1%)
Overall initial unresolved rate: 0.5% (10/1884)
Overall unresolved rate after repeat: 0.0% (0/1882)
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 93.0% (146/157)
Specificity: 95.9% (1653/1724)
Positive Agreement (compared to Direct Culture): 95.0% (133/140)
Negative Agreement (compared to Direct Culture): 95.2% (1657/1741)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
5 2012 JUL
June 1, 2012
510(K) SUMMARY
BD MAX™ MRSA Assay
Submitted by:
GeneOhm Sciences Canada Inc. (BD Diagnostics) 2555, Boul. du Parc-Technologique Québec (Québec) Canada G1P 4S5
Contact:
Patricia Dionne, Ph.D.
Name of Device:
Trade Name: Common Name: Classification Name: BD MAX™ MRSA Assay MRSA detection assay System, Test, Genotypic Detection, resistant and nonresistant markers, Staphylococcus colonies
Predicate Device:
Performance/ Technology
BD GeneOhm™ MRSA ACP Assay (K093346)
Device Description:
Intended Use:
The BD MAX™ MRSA Assay performed on the BD MAX™ System is an automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX™ MRSA Assay is intended to aid in the prevention and control of MRSA infections in healthcare settings. It is not intended to diagnose, quide or monitor MRSA infections. A negative result does not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.
Test Description:
A nasal specimen is collected and transported to the laboratory using the recommended swab. The swab is placed in a BD MAX™ MRSA Sample Buffer Tube. The Sample Buffer Tube is vortexed to release cells from the swab into the buffer. The Sample Buffer Tube is placed onto the BD MAX™ System and the following automated procedures occur: the bacterial cells are lysed, DNA is extracted on magnetic beads and concentrated, then an aliquot of the eluted DNA is added to PCR reagents which contain the MRSA-specific primers used to amplify the genetic target, if present. The assay also
BD Diagnostics BD MAX™ MRSA Assay 510(k) Summary
1
includes a Sample Processing Control (SPC). The Sample Processing Control is present in the Extraction Tube and undergoes the extraction and amplification steps to monitor for inhibitory substances as well as process inefficiency due to instrument or reagent failure. No operator intervention is necessary once the clinical sample and reagent strip are loaded into the BD MAX™ System. The BD MAX™ System automates sample Ivsis. DNA extraction and concentration. reagent rehydration, nucleic acid amplification and detection of the target nucleic acid sequence using real-time polymerase chain reaction (PCR). Amplified targets are detected with hydrolysis probes labeled with quenched fluorophores. The amplification, detection and interpretation of the signals are done automatically by the BD MAX™ System.
The BD MAX™ System uses a combination of lytic and extraction reagents to perform cell lysis and DNA extraction. Following enzymatic cell lysis at elevated temperature, the released nucleic acids are captured by maqnetic affinity beads. The beads with the bound nucleic acids are washed and the nucleic acids are eluted by heat in Elution Buffer. Eluted DNA is neutralized with Neutralization Buffer and transferred to the Master Mix Tube to rehvdrate PCR reagents. The reconstituted amplification reagent is dispensed into the BD MAX™ PCR Cartridge. Microvalves in the BD MAX™ PCR Cartridge are sealed by the system prior to initiating PCR to prevent evaporation and amplicon contamination.
The amplified DNA targets are detected using hydrolysis (TagMan®) probes labeled at one end with a fluorescent reporter dye (fluorophore) and at the other end with a quencher moiety. Probes labeled with different fluorophores are used to detect MRSA and SPC amplicons in two different optical channels of the BD MAX™ System: MRSA amplicons are detected in the FAM channel and SPC amplicons are detected in the ROX channel. When the probes are in their native state, the fluorescence of the fluorophore is quenched due to its proximity to the quencher. However, in the presence of target DNA, the probes hybridize to their complementary sequences and are hydrolyzed by the 5'-3' exonuclease activity of the DNA polymerase as it synthesizes the nascent strand along the DNA template. As a result, the fluorophores are separated from the quencher molecules and fluorescence is emitted. The amount of fluorescence detected in the two optical channels used for the BD MAX™ MRSA Assay is directly proportional to the quantity of the corresponding probe that is hydrolyzed. The BD MAX™ System measures these signals at the end of each amplification cycle, and interprets the data to provide a result.
Substantial Equivalence:
The BD MAX™ MRSA Assay is substantially equivalent in performance to the BD GeneOhm™ MRSA ACP Assay (K093346).
2
Performance data:
Clinical performance characteristics of the BD MAX™ MRSA Assay were determined in a multi-site prospective investigational study. Four (4) investigational centers participated in the study.
The Comparative Reference Method consisted of direct culture complemented by enriched culture. Enriched culture analysis was completed for all specimens that were negative for MRSA by direct culture. Presumptive S. aureus colonies observed on. selective (S. aureus) chromogenic media were subcultured onto Blood Agar (BA). Identification was confirmed with an agglutination test, while Methicillin-resistance was confirmed by Cefoxitin disk (30μg) diffusion susceptibility testing. Enrichment in Trypticase Soy Broth with 6.5% NaCl (TSB 6.5% NaCl) was completed in the event that Methicillin-resistant S. aureus was not confirmed by the initial direct culture method. Turbid TSB 6.5% NaCl broth was used to inoculate additional chromogenic media and BA plates; MRSA confirmation was performed as described above.
Results obtained are summarized in Tables 1 to 5.
Table 1: Results Obtained with the BD MAX™ MRSA Assay in Comparison to the Reference Method
|
.
.
. 25 . 15
| 4
W .
| CHICH
17 100 | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-----------------------|--|
| AND SELL
.
1 25 4 5 = 1 = 1 =
11 13 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
FILL 11 11 23 21 11 11
2019A112 111 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
.
. "
11525652575
.
3-51 6132 111 .
1 1 = 1 = 9 = 4 = 4 = 4 = = = = =
. STARROMASTE
.
11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
14 19 11 1 1 1 1 1 1 1 1 1 1
STAYALL I
. | .
.
.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
| -------------------------------------- | AT REE E E REAM BERRE | |
|
| | | | |
| BD MAX™ MRSA / | | | | |
| In the first of the support of the state of the states | | | 11 | |
1The total number of specimens that were reference and PCR method compliant
Table 2: Performance Obtained using the BD MAX™ MRSA Assay in Comparison to the Reference Method
| Clinical Sites | Prevalence¹ | Sensitivity
with 95% CI² | Specificity
with 95% CI² |
|----------------|-----------------|-----------------------------------|-------------------------------------|
| Site 1 | 5.6% (28/496) | 100.0% (28/28)
(87.9%, 100.0%) | 95.8% (435/454)
(93.6%, 97.3%) |
| Site 2 | 4.6% (23/505) | 91.3% (21/23)
(73.2%, 97.6%) | 96.5% (465/482)
(94.4%, 97.8%) |
| Site 3 | 13.2% (55/417) | 90.9% (50/55)
(80.4%, 96.1%) | 95.8% (346/361)
(93.3%, 97.5%) |
| Site 4 | 10.9% (53/485) | 92.2% (47/51)
(81.5%, 96.9%) | 95.3% (407/427)
(92.9%, 96.9%) |
| Overall³ | 8.4% (159/1903) | 93.0% (146/157)
(87.9%, 96.0%) | 95.9% (1653/1724)
(94.8%, 96.7%) |
Prevalence based on reference method only
CI: Confidence Intervals
3 1903 specimens were reference method compliant
3
Table 3: Results Obtained with the BD MAX™ MRSA Assay in Comparison to Direct Culture
| All Sites | Direct Culture | |||
|---|---|---|---|---|
| + | - | Total | ||
| BD MAX™ MRSA Assay | + | 133 | 84 | 217 |
| BD MAX™ MRSA Assay | - | 7 | 1657 | 1664 |
| Total | 140 | 1741 | 1881 |
Table 4: Performance Obtained using the BD MAX™ MRSA Assay in Comparison to Direct Culture
| Clinical Sites | Positive Agreement
with 95% CI¹ | Negative Agreement
with 95% CI¹ |
|----------------|------------------------------------|-------------------------------------|
| Site 1 | 100.0% (22/22)
(85.1%, 100.0%) | 94.6% (435/460)
(92.1%, 96.3%) |
| Site 2 | 95.5% (21/22)
(78.2%, 99.2%) | 96.5% (466/483)
(94.4%, 97.8%) |
| Site 3 | 94.1% (48/51)
(84.1%, 98.0%) | 95.3% (348/365)
(92.7%, 97.1%) |
| Site 4 | 93.3% (42/45)
(82.1%, 97.7%) | 94.2% (408/433)
(91.6%, 96.1%) |
| Overall | 95.0% (133/140)
(90.0%, 97.6%) | 95.2% (1657/1741)
(94.1%, 96.1%) |
' CI: Confidence Intervals
Table 5: Unresolved Rates
| Clinical Sites | Initial Unresolved Rates
with 95% CI1 | | Unresolved Rates After Repeat
with 95% CI1 | |
|----------------|------------------------------------------|--------------|-----------------------------------------------|--------------|
| Site 1 | 0.8% (4/484) | (0.3%, 2.1%) | 0.0% (0/483) | (0.0%, 0.8%) |
| Site 2 | 0.0% (0/505) | (0.0%, 0.8%) | 0.0% (0/505) | (0.0%, 0.8%) |
| Site 3 | 0.2% (1/416) | (0.0%, 1.3%) | 0.0% (0/416) | (0.0%, 0.9%) |
| Site 4 | 1.0% (5/479) | (0.4%, 2.4%) | 0.0% (0/478) | (0.0%, 0.8%) |
| Overall | 0.5% (10/1884)2 | (0.3%, 1.0%) | 0.0% (0/1882) | (0.0%, 0.2%) |
° CI: Confidence Intervals
² 1884 specimens were PCR method compliant
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name arranged in a circular pattern around the perimeter. At the center is a stylized emblem of an eagle, which is a common symbol used in US government seals.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
BD Diagnostics, Inc c/o Mr. Raymond J. Boulé Director, Regulatory Affairs 7 Loveton Circle, Mail Code 614 Sparks, MD 21152
5 2012 JUL
Re: K120138
Trade/Device Name: BD MAXTM MRSA Assay Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: Class II Product Code: NQX, OOI Dated: June 15, 2012 Received: June 18, 2012
Dear Mr. Boulé:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
5
Page 2 - Mr. Raymond J. Boulé
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
SagaAya
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostics Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Indications for Use Statement
510(k) Number (if known): K120138
Device Name: _________________________________________________________________________________________________________________________________________________________________
Indication(s) for Use:
Intended Use
The BD MAX™ MRSA Assay performed on the BD MAX™ System is an automated qualitative in vitro diagnostic test for the direct detection of Methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The test utilizes real-time polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA. The BD MAX™ MRSA Assay is intended to aid in the prevention and control of MRSA infections in healthcare settings. It is not intended to diagnose, guide or monitor MRSA infections. A negative result does not preclude nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiological typing or for further susceptibility testing.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (per 21 CFR §801, Subpart D) OR
Over-The-Counter Use (per 21 CFR §801, Subpart C) [Optional Format 01/02/1996]
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices Evaluation and Safety (OIVD)
Fredda M. Poole
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
510(k): K120138